SCHEMBL28022065

SCHEMBL28022065

CCC(=O)Nc1ccc(S(=O)(=O)c2nc(Nc3cc(C4CC4)n[nH]3)cc(-c3ccccc3)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKB Q96GD4 5/20 0.47
▸ MAPT P10636 4/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ AURKA O14965 3/20 0.43
▸ ADORA3 P0DMS8 4/20 0.42
▸ ADORA2A P29274 4/20 0.42
▸ ADORA1 P30542 3/20 0.42
▸ ADORA2B P29275 2/20 0.42
▸ ATM Q13315 1/20 0.40
▸ EGFR P00533 2/20 0.40
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ MOK Q9UQ07 1/20 0.37
▸ SRC P12931 1/20 0.36
▸ GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28021591 0.88 AURKB (0.51) AURKBMAPTKDM4EMEN1KMT2A
SCHEMBL2205762 0.83 AURKB (0.69) AURKBMAPTKDM4EMEN1KMT2A
SCHEMBL28553059 0.82 ADORA1 (0.45) AURKBMAPTMEN1KMT2AAURKA
SCHEMBL28562449 0.82 BPTF (0.38) MAPTKMT2AALDH1A1ADORA3ADORA2A
SCHEMBL28022116 0.79 ADORA1 (0.47) AURKBMAPTKDM4EMEN1KMT2A
SCHEMBL28749235 0.79 ADORA3 (0.47) AURKBMAPTKDM4EMEN1KMT2A
SCHEMBL28565368 0.79 AURKB (0.44) AURKBMAPTKDM4EMEN1KMT2A
SCHEMBL28552772 0.79 SDHB (0.41) MAPTKDM4EKMT2AALDH1A1HPGD
SCHEMBL28557357 0.78 AURKB (0.49) AURKBMAPTKDM4EMEN1KMT2A
SCHEMBL28548957 0.76 ADORA1 (0.44) AURKBMAPTKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112755193-A Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof 德玛医药 2021-05-07 — — CN disclosed
CN-104797267-A Method of treating tyrosine kinase inhibitor-resistant malignancies in patients with genetic polymorphism or AHI1 dysregulation or mutation using dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof DEL MAR PHARMACEUTICALS 2015-07-22 — — CN disclosed
Send feedback